Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.63 USD | +0.77% | -4.36% | -10.85% |
Financials (USD)
Sales 2024 * | 3.5M | Sales 2025 * | 9.13M | Capitalization | 96.66M |
---|---|---|---|---|---|
Net income 2024 * | -105M | Net income 2025 * | -78M | EV / Sales 2024 * | 63.4 x |
Net Debt 2024 * | 125M | Net Debt 2025 * | 115M | EV / Sales 2025 * | 23.1 x |
P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-1.55
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.99% |
Latest transcript on BioXcel Therapeutics, Inc.
1 day | +0.77% | ||
1 week | -7.72% | ||
Current month | -6.74% | ||
1 month | -8.68% | ||
3 months | -23.32% | ||
6 months | -13.20% | ||
Current year | -10.85% |
Managers | Title | Age | Since |
---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
Director of Finance/CFO | 66 | 17-09-30 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 22-06-30 |
Peter Mueller
CHM | Chairman | 68 | 17-03-31 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 9 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.63 | +0.77% | 260,295 |
24-04-25 | 2.61 | -3.69% | 665,832 |
24-04-24 | 2.71 | -8.75% | 880,929 |
24-04-23 | 2.97 | +4.21% | 408,518 |
24-04-22 | 2.85 | +3.64% | 369,752 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.85% | 96.66M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- BTAI Stock